^
    Back
    Association details:
    Biomarker:ERBB3 mutation
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    barecetamab (ISU104) (HER3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    SNS-301 added to pembrolizumab in patients (Pts) with ASPH+ advanced squamous cell carcinoma of the head & neck (SCCHN)

    Published date:
    09/14/2020
    Excerpt:
    ISU104 alone or combination with CET was safe and tolerable with encouraging clinical outcomes in R/M HNSCC treated with Comb. A phase II study of weekly ISU104 in combination with approved dose of CET is planned to further establish the clinical utility of ISU104.
    Trial ID:
    SNS-301-2-2